Immune checkpoint inhibitors (ICIs) targeting the programmed cell death receptor-1 and its ligand have achieved impressive success in treating patients with advanced-stage non-small cell lung cancer (NSCLC) after failed first-line cytotoxic chemotherapy. However, knowledge on clinical biomarkers that could help select patients who will respond well to second-line ICI therapy is limited.

中文翻译：

---

晚期非小细胞肺癌患者二线免疫检查点抑制剂的预后因素：一项多中心、回顾性研究。

针对程序性细胞死亡受体-1 及其配体的免疫检查点抑制剂 (ICI) 在一线细胞毒性化疗失败后治疗晚期非小细胞肺癌 (NSCLC) 患者方面取得了令人瞩目的成功。然而，关于可以帮助选择对二线 ICI 治疗反应良好的患者的临床生物标志物的知识是有限的。